1 / 20

European Society of Cardiology Congress 2012 Munich, Germany

ACCESS-EUROPE Phase I A Post Market Study of the MitraClip System for the Treatment of Significant Mitral Regurgitation in Europe: Analysis of Outcomes at 1 Year Wolfgang Schillinger, MD on behalf of the ACCESS EU investigators. European Society of Cardiology Congress 2012 Munich, Germany.

neron
Télécharger la présentation

European Society of Cardiology Congress 2012 Munich, Germany

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ACCESS-EUROPE Phase I A Post Market Study of the MitraClip System for the Treatment of Significant Mitral Regurgitation in Europe: Analysis of Outcomes at 1 Year Wolfgang Schillinger, MD on behalf of the ACCESS EU investigators European Society of Cardiology Congress 2012 Munich, Germany

  2. Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

  3. Transcatheter Mitral Valve RepairMitraClip® System

  4. MitraClip TherapyWorldwide Clinical Experience • Over 6,000 patients have been treated with the MitraClip device worldwide: • 75% are considered high risk* for mitral valve surgery • 67% have functional mitral regurgitation (MR) • 1,905 patients have been enrolled in prospective clinical trials worldwide: • 50% are considered high risk* for mitral valve surgery • 60% have functional MR Estimates of worldwide clinical experience as of 7/20/2012. * Determination of high surgical risk based on: logistic EuroSCORE ≥ 20%, or STS calculated mortality ≥ 12%, or pre-specified high surgical risk co-morbidities specified in EVEREST II High Risk Study protocol.

  5. Introduction • The ACCESS-EUROPE (ACCESS-EU) Study is a two-phase prospective, observational, multicenter, post-approval study of the MitraClip® System for the treatment of significant MR • ACCESS-EU Phase I enrollment started on October 2, 2008 and closed on April 13, 2011. The last follow-up occurred on June 15, 2012. • ACCESS-EU Phase II was initiated on September 15, 2011

  6. Purpose To present 1-year outcomes in patients with significant MR treated with the MitraClip device in the ACCESS-EU Phase I Trial To highlight data, including: Procedural and 30 day safety 1-year outcomes Kaplan-Meier freedom from death MR, NYHA Functional Class and QOL (MLWHF) 6 Minute Walk distance

  7. Enrolling Centers: ACCESS EU Phase I 14 centers have enrolled MitraClip patients

  8. Patient Accountability 1 Year Follow-up N = 487 MitraClip Patients Treated in ACCESS-EU N = 567 N = 3 Data not available N = 13 Withdrawals Discharge N = 551 N = 22 Data not available N = 45 Withdrawals 1-year follow-up complete 86% patient data available

  9. Baseline Demographics and Co-Morbidities

  10. Baseline Demographics and Co-Morbidities

  11. MitraClip Implant Rate and Number of Clips Implanted 99.6% Implant Rate N=567

  12. Post-Procedure and Discharge Results * Denominators smaller than 567 reflect missing data.

  13. Site Reported Safety Events At 30 Days * As reported by the sites

  14. Kaplan-Meier Freedom from Death 30 Days 97.4% 95.6% 96.6% 1 Year 86.4% 76.3% 81.8% p<0.05 Logistic EuroSCORE <20% (N=314) Logistic EuroSCORE ≥20% (N=253) All Patients (N=567)

  15. Site Reported Safety Events At 1 Year * As reported by the sites

  16. Mitral Regurgitation Grade* p<0.0001 0 2+ 1+ 3+ 79% MR ≤ 2+ at 1 Year 2+ 4+ 3+ 4+ N = 327 Matched Cases * As assessed by the sites

  17. NYHA Functional Class p<0.0001 I II I II III III IV IV 72% NYHA Class I or II at 1 Year N = 343 Matched Cases

  18. Quality of Life Score (MLHFQ) and 6-Minute Walk Distance MLHFQ 6MWT p<0.0001 p<0.0001 Mean improvement -13.5 points 95% CI: (-16.0, -11.0) Mean improvement 59.5 meters 95% CI: (44.5, 74.6) Baseline 1 Year Baseline 1 Year N = 264 Matched Cases N = 216 Matched Cases

  19. Summary • Patients treated in the ACCESS-EU study were elderly, symptomatic and had multiple major co-morbidities, indicating the high risk nature of this patient population. • A high device implant success and a low rate of a procedural safety events demonstrate that the MitraClip device can be performed safely in this complex patient population. • ACCESS-EU 1-year results show that the MitraClip device safely reduces MR and provides meaningful clinical benefits, including significant improvements in: • NYHA Functional Class • Quality-of-Life (MLHFQ) • Six-Minute Walk Distance

  20. Conclusion • The MitraClip procedure provides significant clinical benefits to patients with severe MR in a real world setting consistent with results in controlled clinical trials. • The MitraClip therapy therefore provides a treatment option for a patient population with an important unmet clinical need.

More Related